Global private equity firm Warburg Pincus has agreed to sell a 16 percent stake in China-based biopharmaceutical company China Biologic Products for US$425.7 million via a secondary offering on the NASDAQ Stock Market. Warburg Pincus originally invested in the company in 2010 in a transaction structured through Warburg Pincus Private Equity X. The company manufactures more than 20 different dosage forms of plasma products, which are used during medical emergencies and for the prevention and treatment of life-threatening and immunodeficiency diseases.